We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
News

UCB Launches Strategic Research Alliance with Weill-Cornell Medical College

UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
News

UCB Launches Strategic Research Alliance with Weill-Cornell Medical College

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "UCB Launches Strategic Research Alliance with Weill-Cornell Medical College"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

UCB has announced that it has launched a major strategic research alliance with Weill-Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need.

This research alliance reflects UCB’s belief that science progresses more rapidly when innovation is fostered by strong partnerships with leading academic partners.

UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill-Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine.

The research programs are aligned with a key strategy of UCB NewMedicines™ to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.

Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said, “No single organization can work alone to translate cutting-edge fundamental scientific research into transformative medicines for people with severe disease. That is why are creating a super network with trusted scientific partners globally, combining knowledge of patient medical need with understanding of disease mechanisms. This strategic research alliance brings together Weill Cornell’s world class academic research with our discovery team with the shared objective of developing medicines that could transform the lives of people with severe diseases.”

“We are thrilled to enter into this strategic alliance with UCB to drive research discoveries made at the bench into the most advanced treatments for patients in the clinic,” Dr. Glimcher said. “UCB has an accomplished track record of developing first-rate treatments and therapies. With complementary expertise and a common mission - to help patients, improve health and save lives - our alliance will demonstrate the power of academic-industry collaboration.”

Advertisement